Company Research Report: Hikma Pharmaceuticals PLC

Company Overview

• Name: Hikma Pharmaceuticals PLC

• Mission: To bring high-quality medicines within reach of those who need them, helping to shape a healthier world that enriches communities.

• Founded: In 1978 by Samih Darwazah

• Key People:

• Said Darwazah, Chairman

• Riad Mishlawi, CEO

• Mazen Darwazah, Executive Vice Chairman, President of MENA

• Dr. Bill Larkins, President, Injectables

• Brian Hoffmann, President, Generics

• Headquarters: Amman, Jordan (originally), with significant operations in London, UK.

• Number of Employees: Approximately 9,100

• Revenue:

• Injectables: $1,203 million in 2023

• Branded: $714 million in 2023

• Generics: $937 million in 2023

• Known For: Third largest supplier of generic injectables in the US, second largest pharmaceutical company in MENA.

Products

• Injectables: Hikma supplies hospitals with generic injectable products supported by manufacturing facilities in the US, Europe, and MENA.

• Key Features: Large and growing portfolio with over 160 products.

• Branded: Supplies branded generics and in-licensed patented products in MENA.

• Key Features: Focus on cancer and chronic conditions, with extensive manufacturing facilities in MENA.

• Generics: Supplies oral and other non-injectable generic products to the US retail market.

• Key Features: Differentiated technologies, including inhalation and nasal sprays; largest supplier of nasal sprays in the US.

Recent Developments

• Acquisitions:

• Completed acquisition of Xellia Pharmaceuticals’ US finished dosage form business, enhancing injectables portfolio.

• Product Launches:

• Foscarnet Sodium Injection in the US for treatment of CMV retinitis and acyclovir-resistant HSV infections.

• Clindamycin in 5% Dextrose Injection in various dosages for treating infections like septicemia, and gynecological infections.

• Partnerships:

• Expanded strategic partnerships across the MENA region with companies like Guardant Health and Rakuten Medical for innovative health solutions.

• Investments:

• Expanding manufacturing capabilities, particularly in US and MENA, through acquisitions and construction of new R&D facilities.

• Awards:

• Received prestigious recognitions for leadership and company performance in 2024.

This report provides comprehensive insights into Hikma Pharmaceuticals PLC, covering foundational and operational areas crucial for understanding its market positioning and strategic pursuits.